Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 8/20 | 0.43 |
| ▸ | HTR6 | P50406 | 9/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.33 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16618865 | 0.99 | RORC (0.43) | RORCHTR6FBP1CNR2SLC20A2 | |
| SCHEMBL16626502 | 0.92 | HTR6 (0.42) | HTR6FBP1SLC20A2SLC20A1 | |
| Hydrochloric Acid SCHEMBL16618540 | 0.91 | HTR6 (0.42) | HTR6FBP1SLC20A2SLC20A1 | |
| SCHEMBL16626506 | 0.90 | RORC (0.42) | RORCHTR6 | |
| SCHEMBL16626740 | 0.90 | HTR6 (0.43) | HTR6CNR2 | |
| Hydrochloric Acid SCHEMBL16618665 | 0.89 | RORC (0.41) | RORCHTR6 | |
| Hydrochloric Acid SCHEMBL16618768 | 0.89 | HTR6 (0.43) | HTR6CNR2 | |
| SCHEMBL16626512 | 0.88 | HTR6 (0.40) | RORCHTR6CNR2SLC20A2SLC20A1 | |
| Hydrochloric Acid SCHEMBL16619066 | 0.88 | HTR6 (0.39) | RORCHTR6CNR2SLC20A2SLC20A1 | |
| SCHEMBL16626504 | 0.85 | RORC (0.40) | RORCHTR6FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052484-B1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2018-03-21 | — | — | EP | claimed |
| EP-3052484-B1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2018-03-21 | — | — | EP | disclosed |
| US-9676714-B2 | Sulfonylindole derivatives and method for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-04 | — | — | US | disclosed |
| WO-2015050412-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | GIPR, PGC, SI | RORC 1067/4885HTR6 166/4885FBP1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.